In addition, we, and I suspect many others, used to regard JGH as “the port of last call” when what had seemed like promising research had been rejected by other journals, most often more than one! There are several CHIR-99021 mw reasons why this should no longer be the case. First, because JGH no longer publishes retrospective clinical series, small prospective series lacking novelty, or minor advances in experimental research. As the quality of biomedical literature in general and JGH in particular increases, only clinical advances that have new insights and broader interest, and more complete, multi-dimensional experimental studies that
seem close to clinical application are required (no more cell line manipulations please!). Second, it is getting very difficult to publish in GASTROENTEROLOGY, HEPATOLOGY, GUT and similar. Why not consider JGH more often as your “first port of call”, or at worst, your second avenue to publication
after rejection from one of these very top journals. Until 3 years ago, one reason might have been because articles could take 9 months to appear in JGH after their (occasionally tardy) review! Today, your “just accepted” original article will be available as an official electronic document as “accepted copy” within 2 weeks, and then the article will be in print between 4 and 6 months from now (median 5 months). Not many journals can offer better than that in 2012–13.
Third, JGH will soon no longer be a “low IF journal” (IF < 3). The C646 nmr 2011 IF is 2.85, and the major growth since 2011 allows us to confidently forecast a 2012 IF > 3—that of a “medium IF journal”. It may take another 3–5 years for our IF to surpass 5, but if you send us your best work rather than your leftovers we will reach it sooner! If medchemexpress we continue to receive high quality original articles, solicit a reasonable number of excellent reviews of great educational value, and work hard on Consensus Guidelines in our region to be published in JGH, there is no doubt in my mind that this journal will eventually become one of the top ten in our speciality. JGH has been a unifying force in gastroenterology and hepatology in the Asia-Pacific region. Its further development in the specialty now requires an even more concerted focus by experienced regional leaders, rather than dispersing effort across a broad international front. As an author I have not regretted my strong association with the Journal, and with any luck and good health such will continue to unfold for some time yet. As an editor, I have enjoyed the privilege of reading, assessing and editing innumerable interesting contributions in my own field, and have learnt much from others in which I am not an expert.
Related posts:
- Vinorelbine suspect that the increase in the permeability t in response to ANG II Haupts
- The rarity of primary hepatic NET makes it difficult to suspect a
- In addition to provision of brief advice, this included
- Within this regard, ER Inhibitors,Modulators,Libraries differs fr
- With regard to generic prescribing, dispensing and awareness, the